Wir sind mit live! Mehr erfahren
PACB-Symbol

Pacific Biosciences
PACB

1,73 USD
-0,23
11,73 %
Zum Börsenschluss Aktualisiert 16. Okt., 16:00 EDT
Vor Börsenbeginn
Nachbörslich
1,73
0,00
0 %
1 Tag
-11,73 %
5 Tage
-22,77 %
1 Monat
29,1 %
3 Monate
16,11 %
6 Monate
6,13 %
Seit Jahresbeginn
-5,98 %
1 Jahr
-1,7 %
5 Jahre
-92,88 %
10 Jahre
-79,65 %
 

Profil: Pacific Biosciences of California Inc is a biotechnology company focused on designing, developing, and manufacturing sequencing solutions that enable scientists and clinical researchers to improve their understanding of the genome and ultimately, resolve genetically complex problems. It operates in, one reportable segment: the development, manufacturing, and marketing of an integrated platform for genetic analysis. The majority of the company's revenue is derived from Americas, followed by Europe Middle East, and Africa and Asia-Pacific.

Mitarbeiter: 485

Gesundheitswesen Medizintechnik

Nachrichten

Positiv
Neutral
Negativ
Stimmung 3 Monate
Positiv 24,1 %
Neutral 55,2 %
Negativ 20,7 %
Neutral
Zacks Investment Research
vorgestern
Pacific Biosciences of California (PACB) Declines More Than Market: Some Information for Investors
In the most recent trading session, Pacific Biosciences of California (PACB) closed at $1.99, indicating a -2.93% shift from the previous trading day.
Pacific Biosciences of California (PACB) Declines More Than Market: Some Information for Investors
Neutral
GlobeNewsWire
vorgestern
PacBio to Report Third Quarter 2026 Financial Results on November 4, 2026
MENLO PARK, Calif., Oct. 14, 2026 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB) announced today that it will hold its quarterly conference call to discuss its third quarter 2026 financial results on Wednesday, November 4, 2026, at 4:30 p.m. Eastern Time (1:30 p.m. Pacific Time).
PacBio to Report Third Quarter 2026 Financial Results on November 4, 2026
Positiv
Zacks Investment Research
vor 3 Tagen
PacBio Teams With TychoBio to Advance AI-Driven RNA Therapeutics
PACB partners with TychoBio to harness AI and long-read RNA sequencing for rare disease therapies, aiming to improve drug efficacy and safety through advanced data models.
PacBio Teams With TychoBio to Advance AI-Driven RNA Therapeutics
Neutral
Zacks Investment Research
vor 8 Tagen
Why Pacific Biosciences of California (PACB) Dipped More Than Broader Market Today
The latest trading day saw Pacific Biosciences of California (PACB) settling at $2.3, representing a -15.44% change from its previous close.
Why Pacific Biosciences of California (PACB) Dipped More Than Broader Market Today
Neutral
GlobeNewsWire
vor 11 Tagen
PacBio and TychoBio Collaborate to Train AI Models for Rare Disease RNA Therapeutics
PacBio Kinnex sequencing will generate full-length transcript data to help advance TychoBio's drug discovery models PacBio Kinnex sequencing will generate full-length transcript data to help advance TychoBio's drug discovery models
PacBio and TychoBio Collaborate to Train AI Models for Rare Disease RNA Therapeutics
Neutral
Zacks Investment Research
vor 14 Tagen
Pacific Biosciences of California (PACB) Rises Higher Than Market: Key Facts
Pacific Biosciences of California (PACB) concluded the recent trading session at $2.54, signifying a +1.2% move from its prior day's close.
Pacific Biosciences of California (PACB) Rises Higher Than Market: Key Facts
Neutral
Schaeffers Research
vor 15 Tagen
3 Biotech Stocks Put Traders Are Targeting Today
Nektar Therapeutics (NASDAQ:NKTR), Quantum-Si Inc (NASDAQ:QSI), and Pacific Biosciences of California Inc (NASDAQ:PACB) are all attracting elevated options activity today, as biotech stocks make volatile moves.
3 Biotech Stocks Put Traders Are Targeting Today
Positiv
Zacks Investment Research
vor 21 Tagen
Pacific Biosciences of California (PACB) Beats Stock Market Upswing: What Investors Need to Know
In the latest trading session, Pacific Biosciences of California (PACB) closed at $1.62, marking a +2.53% move from the previous day.
Pacific Biosciences of California (PACB) Beats Stock Market Upswing: What Investors Need to Know
Positiv
MarketBeat
vor 27 Tagen
Pacific Biosciences Targets Clinical Growth, $40M Savings With HiFi Sequencing Push
Pacific Biosciences of California NASDAQ: PACB is maintaining its existing strategy while sharpening execution around clinical genomics, cost controls and the rollout of products designed to improve sequencing economics, Chief Executive Officer Mark Van Oene said during a Morgan Stanley discussion.
Pacific Biosciences Targets Clinical Growth, $40M Savings With HiFi Sequencing Push
Positiv
Zacks Investment Research
vor 29 Tagen
Why Pacific Biosciences of California (PACB) Outpaced the Stock Market Today
In the most recent trading session, Pacific Biosciences of California (PACB) closed at $1.38, indicating a +2.99% shift from the previous trading day.
Why Pacific Biosciences of California (PACB) Outpaced the Stock Market Today
Nachrichtenrankings ansehen
Kursdiagramme mit Lightweight Charts™ umgesetzt